PDPHF Stock Chart & Stats
$1.03
-$0.04(-3.57%)
―
--
Day’s Range― - ―
52-Week Range$0.64 - $1.11
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.92K
Market Cap
$476.03M
Enterprise Value$2.34B
Total Cash (Recent Filing)$378.40M
Total Debt (Recent Filing)$68.80M
Price to Earnings (P/E)―
Beta-0.32
Next Earnings
Nov 06, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.01
Shares Outstanding464,965,580
10 Day Avg. Volume303
30 Day Avg. Volume1,924
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)5.81
Price to Sales (P/S)31.51
P/FCF Ratio-7.32
Enterprise Value/Market Cap4.91
Enterprise Value/Revenue35.38
Enterprise Value/Gross Profit210.71
Enterprise Value/Ebitda-6.16
Forecast
1Y Price Target
$3.36Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.06
Revenue Forecast (FY)$67.20M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue growth to 66.1M TTM and acceleration versus recent annual periods indicate improving commercial traction for the rare-disease portfolio. If sustained, a larger revenue base can spread substantial development costs and support stronger operating leverage over the next several quarters.
Moderate LeverageModerate leverage and a sizable equity base provide more financial flexibility than the company’s loss profile alone would suggest. This balance-sheet structure may help Egetis continue funding late-stage development while reducing the immediate pressure associated with excessive debt obligations.
Gross Margin RecoveryThe recovery in gross margin shows that underlying product economics have improved materially from the weakest levels seen in 2022–2023. Although profitability remains distant, maintaining this improvement would strengthen the revenue contribution available to cover operating and development expenses.
Bears Say
Persistent Cash BurnLarge negative operating and free cash flow indicates that the business is not yet self-funding and must continue financing its operations through available capital or future funding. Persistent cash burn can constrain investment choices and increase dependence on successful commercialization or additional financing.
Deep Operating LossesExtremely negative operating and net margins show that expenses remain far above the current revenue base, limiting evidence of operating leverage today. Unless revenue scales substantially or costs decline, the company may remain structurally loss-making through the next several quarters.
Negative Return On EquityA deeply negative return on equity indicates that the capital invested in the business is currently producing losses rather than returns. Continued losses can gradually erode the equity base, reducing balance-sheet resilience and making improving operating performance increasingly important.
Egetis Therapeutics AB News
PDPHF FAQ
What was Egetis Therapeutics AB’s price range in the past 12 months?
Egetis Therapeutics AB lowest stock price was $0.64 and its highest was $1.11 in the past 12 months.
What is Egetis Therapeutics AB’s market cap?
Egetis Therapeutics AB’s market cap is $476.03M.
When is Egetis Therapeutics AB’s upcoming earnings report date?
Egetis Therapeutics AB’s upcoming earnings report date is Nov 06, 2026 which is in 5 days.
How were Egetis Therapeutics AB’s earnings last quarter?
Egetis Therapeutics AB released its earnings results on Aug 21, 2026. The company reported -$0.025 earnings per share for the quarter, missing the consensus estimate of -$0.015 by -$0.01.
Is Egetis Therapeutics AB overvalued?
According to Wall Street analysts Egetis Therapeutics AB’s price is currently Undervalued.
Does Egetis Therapeutics AB pay dividends?
Egetis Therapeutics AB does not currently pay dividends.
What is Egetis Therapeutics AB’s EPS estimate?
Egetis Therapeutics AB’s EPS estimate is -0.02.
How many shares outstanding does Egetis Therapeutics AB have?
Egetis Therapeutics AB has 464,965,580 shares outstanding.
What happened to Egetis Therapeutics AB’s price movement after its last earnings report?
Egetis Therapeutics AB reported an EPS of -$0.025 in its last earnings report, missing expectations of -$0.015. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Egetis Therapeutics AB?
Currently, no hedge funds are holding shares in PDPHF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Egetis Therapeutics AB
Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug sector, concentrating on severe and rare or niche diseases. Its current therapeutic pipeline includes two key drugs undergoing Phase IIb/III clinical trials: Aladote, which is designed to mitigate the risk of acute liver damage associated with acetaminophen/paracetamol poisoning, and Emcitate, intended for the management of MCT8 deficiency, a rare congenital disorder impacting thyroid hormone signaling. Established in 2006, Egetis Therapeutics AB (publ) is headquartered in Stockholm, Sweden, and was previously known as PledPharma AB (publ) until its name change in December 2020.
PDPHF Stock 12 Month Forecast
Average Price Target
$3.36
Technical Analysis
Ownership Overview
―
Insiders
0.09% Mutual Funds
― Other Institutional Investors
99.77% Public Companies and
Individual Investors